Ernexa Therapeutics (ERNA) Short term Debt (2016 - 2025)
Historic Short term Debt for Ernexa Therapeutics (ERNA) over the last 13 years, with Q3 2025 value amounting to $41000.0.
- Ernexa Therapeutics' Short term Debt fell 9916.77% to $41000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $41000.0, marking a year-over-year decrease of 9916.77%. This contributed to the annual value of $1.8 million for FY2022, which is N/A changed from last year.
- As of Q3 2025, Ernexa Therapeutics' Short term Debt stood at $41000.0, which was down 9916.77% from $41000.0 recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Short term Debt registered a high of $4.9 million during Q3 2024, and its lowest value of $41000.0 during Q2 2025.
- In the last 5 years, Ernexa Therapeutics' Short term Debt had a median value of $410000.0 in 2021 and averaged $1.2 million.
- Its Short term Debt has fluctuated over the past 5 years, first tumbled by 7621.81% in 2021, then plummeted by 9916.77% in 2025.
- Over the past 5 years, Ernexa Therapeutics' Short term Debt (Quarter) stood at $410000.0 in 2021, then soared by 326.83% to $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then soared by 181.49% to $4.9 million in 2024, then plummeted by 99.17% to $41000.0 in 2025.
- Its last three reported values are $41000.0 in Q3 2025, $41000.0 for Q2 2025, and $4.9 million during Q3 2024.